Imidazole-Based Synthetic Lipidoids for In Vivo mRNA Delivery into Primary T Lymphocytes

Angew Chem Int Ed Engl. 2020 Nov 2;59(45):20083-20089. doi: 10.1002/anie.202008082. Epub 2020 Aug 28.

Abstract

Engineering T lymphocytes is an emerging approach in a variety of biomedical applications. However, delivering large biologics to primary T lymphocytes directly in vivo is technically challenging due to the low transfection efficacy. Herein, we investigated a library of synthetic lipid-like molecules (lipidoids) for their capability of delivering mRNA into primary T lymphocytes both ex vivo and in vivo. We initially screened a library with a large structural variety of lipidoids ex vivo and identified imidazole-containing lipidoids that are particularly potent in T lymphocytes transfection. We further optimized lipidoid structures by constructing and screening a detailed lipidoid library containing imidazole or imidazole analogues to perform a structure-activity correlation analysis. Using the lead lipidoid as a delivery vehicle for Cre mRNA in vivo through intravenous injection, we achieved 8.2 % gene recombination in mouse T lymphocytes.

Keywords: T cell engineering; combinatorial chemistry; drug delivery; gene therapy; imidazole-containing lipids.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Gene Transfer Techniques
  • HeLa Cells
  • Humans
  • Imidazoles / chemistry*
  • Lipids / chemistry*
  • Mice
  • RNA, Messenger / administration & dosage*
  • T-Lymphocytes / metabolism*

Substances

  • Imidazoles
  • Lipids
  • RNA, Messenger